| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia |
|
Medicine details |
|
| Medicine name | bendamustine (Levact®) |
| Formulation | 2.5 mgml powder for concentrate for solution for infusion |
| Reference number | 56 |
| Indication | First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate |
| Company | Napp Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 05/10/2010 |
| NICE guidance | TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia |